TWI897846B - 可誘導之嵌合細胞激素受體 - Google Patents

可誘導之嵌合細胞激素受體

Info

Publication number
TWI897846B
TWI897846B TW108107136A TW108107136A TWI897846B TW I897846 B TWI897846 B TW I897846B TW 108107136 A TW108107136 A TW 108107136A TW 108107136 A TW108107136 A TW 108107136A TW I897846 B TWI897846 B TW I897846B
Authority
TW
Taiwan
Prior art keywords
domain
cells
cell
receptor
immune cell
Prior art date
Application number
TW108107136A
Other languages
English (en)
Chinese (zh)
Other versions
TW201945402A (zh
Inventor
安德魯 羅斯 納格
史賓瑟 帕克
瑞格斯 嘉維爾 費南多 恰佩羅
君慧 林
布拉康 湯瑪士 約翰 凡
Original Assignee
美商異基因治療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商異基因治療有限公司 filed Critical 美商異基因治療有限公司
Publication of TW201945402A publication Critical patent/TW201945402A/zh
Application granted granted Critical
Publication of TWI897846B publication Critical patent/TWI897846B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW108107136A 2018-03-02 2019-03-04 可誘導之嵌合細胞激素受體 TWI897846B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862637600P 2018-03-02 2018-03-02
US62/637,600 2018-03-02
PCT/US2019/020340 WO2019169290A1 (en) 2018-03-02 2019-03-01 Inducible chimeric cytokine receptors
WOPCT/US2019/020340 2019-03-01

Publications (2)

Publication Number Publication Date
TW201945402A TW201945402A (zh) 2019-12-01
TWI897846B true TWI897846B (zh) 2025-09-21

Family

ID=65952060

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108107136A TWI897846B (zh) 2018-03-02 2019-03-04 可誘導之嵌合細胞激素受體

Country Status (14)

Country Link
US (2) US12163169B2 (cg-RX-API-DMAC7.html)
EP (1) EP3759132A1 (cg-RX-API-DMAC7.html)
JP (2) JP7526101B2 (cg-RX-API-DMAC7.html)
KR (2) KR102842692B1 (cg-RX-API-DMAC7.html)
CN (1) CN111819192A (cg-RX-API-DMAC7.html)
AR (1) AR114273A1 (cg-RX-API-DMAC7.html)
AU (2) AU2019227979B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020017734A2 (cg-RX-API-DMAC7.html)
CA (1) CA3091681A1 (cg-RX-API-DMAC7.html)
IL (2) IL276831B2 (cg-RX-API-DMAC7.html)
MX (2) MX2020009051A (cg-RX-API-DMAC7.html)
SG (1) SG11202007771VA (cg-RX-API-DMAC7.html)
TW (1) TWI897846B (cg-RX-API-DMAC7.html)
WO (1) WO2019169290A1 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
JP7250519B2 (ja) * 2016-03-23 2023-04-03 ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） Ｐｄ－１及び４－１ｂｂの融合タンパク質
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN117384929A (zh) 2017-03-27 2024-01-12 新加坡国立大学 一种编码由细胞表达的嵌合受体的多核苷酸
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
US12163169B2 (en) * 2018-03-02 2024-12-10 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
EP3844186A4 (en) * 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
CA3129862A1 (en) 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a pd-1 ectodomain
KR20210136041A (ko) * 2019-03-01 2021-11-16 알로젠 테라퓨틱스 인코포레이티드 구성적으로 활성인 키메라 사이토카인 수용체
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
EP4041893A4 (en) * 2019-10-08 2023-08-30 Provincial Health Services Authority CHEMERACY CYTOKINE RECEPTORS
KR20220141299A (ko) * 2020-01-14 2022-10-19 신테카인, 인크. Il2 오르토로그 및 사용 방법
PE20221757A1 (es) * 2020-02-24 2022-11-11 Allogene Therapeutics Inc Celulas t con car de bcma con actividades mejoradas
WO2021173586A1 (en) * 2020-02-24 2021-09-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nk cells or t cells expressing hematopoietic growth factor receptors and use for treating cancer
WO2021170666A1 (en) 2020-02-25 2021-09-02 Quell Therapeutics Limited Chimeric receptors for use in engineered cells
PE20230494A1 (es) 2020-05-08 2023-03-23 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas
US20230310606A1 (en) * 2020-07-17 2023-10-05 Simurx, Inc. Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
EP4267601A1 (en) * 2020-12-23 2023-11-01 Quell Therapeutics Limited Inducible signalling protein
WO2022179563A1 (en) * 2021-02-24 2022-09-01 Hangzhou Qihan Biotechnology Co., Ltd. Systems and compositions for enhanced immunotherapies and methods thereof
KR102829018B1 (ko) 2021-03-03 2025-07-04 서울대학교산학협력단 키메릭 항원 수용체-대식 세포의 제조 방법 및 그 세포의 용도
JP2024515577A (ja) * 2021-04-07 2024-04-10 プロヴィンシャル ヘルス サービシーズ オーソリティ 修飾された顆粒球コロニー刺激因子（ｇ－ｃｓｆ）及びこれに結合するキメラサイトカイン受容体
CN113512125B (zh) * 2021-04-26 2024-01-19 北京双赢科创生物科技有限公司 一种携带stat结合基序的嵌合抗原受体分子及表达该嵌合抗原受体分子的nk细胞
KR20240021179A (ko) * 2021-05-14 2024-02-16 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 폴리펩티드 및 사용 방법
WO2023276395A1 (ja) * 2021-06-28 2023-01-05 愛知県 キメラサイトカイン受容体
US20230110313A1 (en) 2021-09-17 2023-04-13 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
GB202117298D0 (en) 2021-11-30 2022-01-12 Quell Therapeutics Ltd Signalling protein
EP4453022A1 (en) 2021-12-22 2024-10-30 Quell Therapeutics Limited Constitutive cytokine receptors
EP4499680A1 (en) 2022-03-29 2025-02-05 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
AU2023297866A1 (en) * 2022-06-28 2024-12-12 Resolution Therapeutics Limited Switch receptors and modified immune cells
CA3260970A1 (en) * 2022-07-11 2024-01-18 The Board Of Trustees Of The Leland Stanford Junior University Tunable Cytokine Receptor Signaling Domains
CN114949000B (zh) * 2022-08-02 2022-10-04 卡瑞济(北京)生命科技有限公司 麝香提取物及其增强car-t细胞疗效的应用
CN117683139A (zh) * 2022-09-09 2024-03-12 信达细胞制药(苏州)有限公司 组成型嵌合细胞因子受体及表达其的免疫细胞及应用
GB202217541D0 (en) 2022-11-24 2023-01-11 Quell Therapeutics Ltd Recombinant receptor
WO2024133472A1 (en) 2022-12-22 2024-06-27 Quell Therapeutics Limited Constitutive cytokine receptors
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
TW202436337A (zh) 2023-01-23 2024-09-16 漢諾威醫學院 嵌合抗原受體
AU2024219048A1 (en) 2023-02-07 2025-08-07 Quell Therapeutics Limited Culture method for treg cells
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024175805A1 (en) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Chimeric antigen receptor
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
WO2024194605A1 (en) 2023-03-17 2024-09-26 Quell Therapeutics Limited Treg therapy
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194355A1 (en) 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024263710A1 (en) 2023-06-20 2024-12-26 Allogene Therapeutics, Inc. Methods of detection for engineered cells
WO2024261480A1 (en) 2023-06-21 2024-12-26 Quell Therapeutics Limited Constitutive cytokine receptors
AU2024310260A1 (en) * 2023-06-29 2025-12-11 Dispatch Biotherapeutics, Inc. Synthetic cytokine receptors
WO2025026347A1 (en) * 2023-07-31 2025-02-06 Nanjing Legend Biotech Co., Ltd. Chimeric cytokine receptors and methods of use thereof
WO2025064779A1 (en) * 2023-09-20 2025-03-27 University Of Southern California Synthetic tgf-beta redirectors and uses thereof in chimeric antigen receptor-mediated cell therapy and others
WO2025076134A1 (en) * 2023-10-03 2025-04-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nk cells or t cells expressing chimeric hematopoietic growth factor receptors and methods of use
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
WO2025096643A1 (en) * 2023-11-01 2025-05-08 Baylor College Of Medicine Reverse fate receptors to enhance the efficacy of engineered t cells
WO2025111277A2 (en) * 2023-11-20 2025-05-30 Carisma Therapeutics Inc. Compositions and methods relating to redirected soluble modulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004389A1 (en) * 1994-08-04 1996-02-15 Regeneron Pharmaceuticals, Inc. Rtk/cytokine receptor chimeras
US20140050709A1 (en) * 2011-04-08 2014-02-20 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
WO2017029512A1 (en) * 2015-08-20 2017-02-23 Autolus Ltd Chimeric cytokine receptor
US20180037630A1 (en) * 2015-02-12 2018-02-08 University Health Network Chimeric Antigen Receptors

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
WO1998002558A2 (en) * 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
JP2004500095A (ja) 2000-02-24 2004-01-08 エクサイト　セラピーズ，　インコーポレイテッド 細胞の同時の刺激および濃縮
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2007075899A2 (en) 2005-12-21 2007-07-05 Maxygen, Inc. Dual agonist compounds and uses thereof
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US20100203067A1 (en) 2008-09-22 2010-08-12 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
WO2011069004A1 (en) 2009-12-04 2011-06-09 Quest Diagnostics Investments Incorporated Mpl mutations in jak2 v617f negative patients with myeloproliferative disease
CN114835823A (zh) 2011-07-29 2022-08-02 宾夕法尼亚大学董事会 转换共刺激受体
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
US9944690B2 (en) 2013-03-14 2018-04-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
JP6467406B2 (ja) 2013-06-05 2019-02-13 ベリカム ファーマシューティカルズ， インコーポレイテッド カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
EP4420663A3 (en) * 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
RU2017115808A (ru) 2014-10-07 2018-11-13 Селлектис Способ модуляции активности car-индуцированных иммунных клеток
WO2016100241A2 (en) 2014-12-15 2016-06-23 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells
US20180002427A1 (en) 2015-01-26 2018-01-04 Cellectis Cll1-specific multi-chain chimeric antigen receptor
AU2016248947B2 (en) 2015-04-13 2020-07-16 Pfizer Inc. Chimeric Antigen Receptors targeting B-Cell Maturation Antigen
US20180318303A1 (en) 2015-04-15 2018-11-08 Promedior, Inc. Methods for treating myeloproliferative disorders
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
WO2019055946A1 (en) * 2017-09-18 2019-03-21 F1 Oncology, Inc. METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF
WO2018161064A1 (en) 2017-03-03 2018-09-07 F1 Oncology, Inc. Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
CN116970630A (zh) 2016-08-26 2023-10-31 贝勒医学院 用于细胞治疗的组成型活性细胞因子受体
CN117720665A (zh) 2016-11-17 2024-03-19 2赛文缇生物公司 TGFβ信号转换器
WO2018104473A1 (en) 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
GB201702617D0 (en) 2017-02-17 2017-04-05 Autolus Ltd Receptor
GB201719557D0 (en) 2017-11-24 2018-01-10 Autolus Ltd Polypeptide
US11738047B2 (en) 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
US12163169B2 (en) 2018-03-02 2024-12-10 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
EP3810645A1 (en) 2018-06-22 2021-04-28 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
CA3129862A1 (en) 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a pd-1 ectodomain
KR20210136041A (ko) 2019-03-01 2021-11-16 알로젠 테라퓨틱스 인코포레이티드 구성적으로 활성인 키메라 사이토카인 수용체

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004389A1 (en) * 1994-08-04 1996-02-15 Regeneron Pharmaceuticals, Inc. Rtk/cytokine receptor chimeras
US20140050709A1 (en) * 2011-04-08 2014-02-20 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
US20180037630A1 (en) * 2015-02-12 2018-02-08 University Health Network Chimeric Antigen Receptors
WO2017029512A1 (en) * 2015-08-20 2017-02-23 Autolus Ltd Chimeric cytokine receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Olli Silvennoinen, et al., "Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors", APMIS, Vol.105, Issue7-12, 無, July 1997, Pages 497-509
期刊 Tim Clackson, et al., "Redesigning an FKBP–ligand interface to generate chemicaldimerizers with novel specificity", Proc. Natl. Acad. Sci. USA, Vol. 95, 無, September 1998, pages 10437–10442;期刊 Leila N. Varghese, et al., " The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin", Frontiers in Endocrinology, Vol.8, No.59, 31 March 2017, doi: 10.3389/fendo.2017.00059;期刊 Rhiannon Morris, Nadia J. Kershaw,and Jeffrey J. Babon, "The molecular details of cytokine signaling via the JAK/STAT pathway", Protein Science, Volume27, Issue12, 無, 29 September 2018, Pages 1984-2009;期刊 Jeffrey J. BABON, et al., "The molecular regulation of Janus kinase (JAK) activation", Biochemical Journal, Vol. 462, Issue 1, 無, August 2014, Pages 1-13;期刊 Olli Silvennoinen, et al., "Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors", APMIS, Vol.105, Issue7-12, 無, July 1997, Pages 497-509 *

Also Published As

Publication number Publication date
US12163169B2 (en) 2024-12-10
SG11202007771VA (en) 2020-09-29
RU2020128082A (ru) 2022-04-04
JP7526101B2 (ja) 2024-07-31
US20190292533A1 (en) 2019-09-26
KR20250123938A (ko) 2025-08-18
IL317065A (en) 2025-01-01
CA3091681A1 (en) 2019-09-06
IL276831B2 (en) 2025-04-01
AU2024278090A1 (en) 2025-01-09
JP2024074801A (ja) 2024-05-31
AU2019227979B2 (en) 2024-09-05
KR102842692B1 (ko) 2025-08-04
WO2019169290A1 (en) 2019-09-06
CN111819192A (zh) 2020-10-23
TW201945402A (zh) 2019-12-01
US20250333719A1 (en) 2025-10-30
JP2021514677A (ja) 2021-06-17
MX2020009051A (es) 2020-12-03
KR20200128054A (ko) 2020-11-11
EP3759132A1 (en) 2021-01-06
AU2019227979A1 (en) 2020-08-27
IL276831A (en) 2020-10-29
IL276831B1 (en) 2024-12-01
MX2025009955A (es) 2025-09-02
AR114273A1 (es) 2020-08-12
BR112020017734A2 (pt) 2020-12-29

Similar Documents

Publication Publication Date Title
TWI897846B (zh) 可誘導之嵌合細胞激素受體
JP7633937B2 (ja) Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体
EP3341410B1 (en) Chimeric antigen receptors with integrated controllable functions
KR20230153529A (ko) 다양한 면역세포를 위한 단일사슬 및 다중사슬 합성 항원 수용체
CN114341193A (zh) 包括tgfβ结合结构域的嵌合细胞因子受体
KR20230142470A (ko) 동종이계 세포 산물의 T 세포 인식을 완화하기 위한TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP, 및 RFXANK 중 하나 이상의 녹다운 또는 녹아웃
RU2826155C2 (ru) Индуцибельные химерные цитокиновые рецепторы
RU2824672C2 (ru) Конститутивно активные химерные цитокиновые рецепторы
RU2842294C1 (ru) Химерные цитокиновые рецепторы, содержащие домены, связывающие tgf-бета